J&J announce first-of-its-kind portopulmonary hypertension study results
The findings “Provide important clinical evidence to help inform treatment decisions and fill an unmet need that should benefit patients living with PoPH.”
Read More
Tag: Opsumit
Actelion’s Opsumit shows promise in portopulmonary hypertension
Actelion has unveiled new data showing that the first ever randomised, controlled clinical trial investigating Opsumit as potential treatment for portopulmonary hypertension (PoPH) hit its primary target.
Read More
Actelion’s PAH drug fails to hit target in PhIII study
Actelion has suffered a setback in its quest to expand the uses of Tracleer follow-up Opsumit, after a study assessing the drug in patients with pulmonary arterial hypertension (PAH) due to Eisenmenger Syndrome failed to meet its primary goal.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
